|
Extraskeletal Myxoid Chondrosarcoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Most, although not all, examples of EMC possess a unique balanced chromosomal translocation [t(9;22)(q22;q12)] between the EWSR1 and NR4A3 (previously termed TEC) genes.
|
22804337 |
2012 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Extraskeletal myxoid chondrosarcoma (EMC) is characterized by recurrent chromosomal translocations resulting in fusions of the nuclear receptor gene NOR1 (also known as CHN or TEC) to various N-terminal partners, including EWS and TAF2N (or RBP56).
|
15188455 |
2004 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
The EWS/TEC fusion protein encoded by the t(9:22) chromosomal translocation in human extraskeletal myxoid chondrosarcoma tumors is thought to participate in the tumoral process at least in part by deregulating the expression of specific target genes involved in the control of cell proliferation.
|
12049818 |
2002 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Fusion of the NH2-terminal domain of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t(9;15)(q22;q21).
|
11156374 |
2000 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma.
|
10537274 |
1999 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data demonstrated that ECM-associated genes play pivotal roles in breast cancer EC biology and some of them could serve as potential TEC biomarkers for various cancers.
|
29541388 |
2018 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data demonstrated that ECM-associated genes play pivotal roles in breast cancer EC biology and some of them could serve as potential TEC biomarkers for various cancers.
|
29541388 |
2018 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The bioengineered model recapitulated vasculogenic mimicry (vessel-like structure formation and tumor-derived endothelial cells-TECs), and contained CSLC expressing SOX2 and NANOG.
|
29158813 |
2017 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our study support the view that BC cases under the TEC chemotherapy were related to higher overall response rates; and the chemotherapy with the TEC regimen could be served as an effective therapy in the treatment of BC.
|
25480315 |
2015 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our study support the view that BC cases under the TEC chemotherapy were related to higher overall response rates; and the chemotherapy with the TEC regimen could be served as an effective therapy in the treatment of BC.
|
25480315 |
2015 |
|
Chondrosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Because the NTDs of TFG-TEC and TEC are structurally different, and the TFG itself is a cytoplasmic protein, the functional consequences of this fusion in extraskeletal myxoid chondrosarcomas were examined.
|
22581839 |
2012 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Fifty-nine Taiwanese women (mean age, 46 y; range, 30-64 y) treated for breast cancer with TEC were recruited.
|
19332043 |
2009 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Fifty-nine Taiwanese women (mean age, 46 y; range, 30-64 y) treated for breast cancer with TEC were recruited.
|
19332043 |
2009 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
All tumors contained translocation-generated or cryptic gene fusions, including EWS-TEC (five cases, of which one was a novel fusion), TAF2N-TEC (four cases), and TCF12-TEC (one case). cDNA microarray analysis of the gene expression patterns of two EMCs and a myxoid liposarcoma reference tumor revealed a remarkably distinct and uniform expression profile in both EMCs despite the fact that they had different histologies and expressed different fusion transcripts.
|
12598313 |
2003 |
|
Chondrosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results suggest that EWS/TEC interacts at least in part with the same transcriptional coactivators as the native TEC receptor, and that these coactivators may be involved in the tumoral process leading to human chondrosarcoma tumors.
|
12049818 |
2002 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
These results suggest that EWS/TEC interacts at least in part with the same transcriptional coactivators as the native TEC receptor, and that these coactivators may be involved in the tumoral process leading to human chondrosarcoma tumors.
|
12049818 |
2002 |
|
Adult Extraskeletal Myxoid Chondrosarcoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The EWS/TEC fusion protein encoded by the t(9:22) chromosomal translocation in human extraskeletal myxoid chondrosarcoma tumors is thought to participate in the tumoral process at least in part by deregulating the expression of specific target genes involved in the control of cell proliferation.
|
12049818 |
2002 |
|
Adult Extraskeletal Myxoid Chondrosarcoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Fusion of the NH2-terminal domain of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t(9;15)(q22;q21).
|
11156374 |
2000 |
|
Chondrosarcoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator.
|
10359536 |
1999 |
|
Adult Extraskeletal Myxoid Chondrosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma.
|
10537274 |
1999 |
|
Post-Traumatic Stress Disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
To examine effects of PTSD and MJ use on brain structure, we performed diffusion tensor imaging scans on seventy-two trauma-exposed participants, categorized into four groups: those with PTSD who used MJ at least weekly (PTSD+MJ; n = 20), those with PTSD with no regular MJ use (PTSD; n = 19), trauma-exposed controls without PTSD who used MJ (TEC+MJ; n = 14) and trauma-exposed controls with no PTSD or MJ use (TEC; n = 19).
|
31760337 |
2020 |
|
Post-Traumatic Stress Disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
Further, GABA/H<sub>2</sub>O in the dACC correlated negatively with sleep symptoms in the PTSD group (p = 0.03) but not in the TEC and NTEC groups.
|
30735853 |
2019 |
|
Autoimmune Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
IFN-γ(-/-) NOD.H-2h4 mice develop autoimmune disease with extensive hyperplasia and proliferation of thyroid epithelial cells (TEC H/P) and fibrosis.
|
27173733 |
2017 |
|
Autoimmune Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Here we show that mice with mTEC depletion due to conditional deletion of Traf6 expression in murine thymic epithelial cells (Traf6ΔTEC mice) showed a surprisingly narrow spectrum of autoimmunity affecting the liver.
|
23867620 |
2013 |
|
Renal Cell Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings suggested that PTGFR is a novel TEC marker and that it may be a novel target for antiangiogenic therapy for RCC.
|
23356224 |
2013 |